Lithuania vs Serbia: Expenditure on sickness and health care function by type of benefit
Lithuania
3,906 Million euro
in 2023
Serbia
4,651 Million euro
in 2024
Lithuania rank
34th
Serbia rank
33rd
Expenditure on sickness and health care function by type of benefit over time
- Lithuania
- Serbia
How they compare
Serbia currently reports 4,651 Million euro against 3,906 Million euro in Lithuania, a difference of 745 Million euro.
That makes Serbia's figure about 1.2 times Lithuania's.
The two have swapped places 4 times across 16 shared years of data; in 2008 it was Serbia ahead.
Lithuania ranks 34th and Serbia ranks 33rd of 45 countries.
Serbia has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Lithuania | Serbia | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 1,482 Million euro | 2,020 Million euro | 538.31 Million euro | Serbia |
| 2010s | 1,693 Million euro | 1,978 Million euro | 284.24 Million euro | Serbia |
| 2020s | 3,328 Million euro | 3,440 Million euro | 112.04 Million euro | Serbia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher expenditure on sickness and health care function by type of benefit, Lithuania or Serbia?
- Serbia, at 4,651 Million euro against 3,906 Million euro in Lithuania as of 2024.
- What is the difference in expenditure on sickness and health care function by type of benefit between Lithuania and Serbia?
- 745 Million euro, with Serbia ahead.
- How many years of comparable data are there for Lithuania and Serbia?
- 16 years are reported by both, from 2008 to 2023.
- How do Lithuania and Serbia rank globally for expenditure on sickness and health care function by type of benefit?
- Lithuania ranks 34th and Serbia ranks 33rd of 45 countries.
- Where does this data come from?
- Eurostat, published as Expenditure on sickness and health care function by type of benefit and means-testing. Statizoid refreshes it automatically from the source and publishes the full history for both places.